These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36428217)

  • 1. Practical implementation of the partial ordering continual reassessment method in a Phase I combination-schedule dose-finding trial.
    Mozgunov P; Jaki T; Gounaris I; Goddemeier T; Victor A; Grinberg M
    Stat Med; 2022 Dec; 41(30):5789-5809. PubMed ID: 36428217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-finding design for multi-drug combinations.
    Wages NA; Conaway MR; O'Quigley J
    Clin Trials; 2011 Aug; 8(4):380-9. PubMed ID: 21652689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation.
    Abbas R; Rossoni C; Jaki T; Paoletti X; Mozgunov P
    Clin Trials; 2020 Oct; 17(5):522-534. PubMed ID: 32631095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quasi-partial order continual reassessment method: Applying toxicity scores to cancer dose-finding drug combination trials.
    O'Connell NS; Wages NA; Garrett-Mayer E
    Contemp Clin Trials; 2023 Feb; 125():107050. PubMed ID: 36529437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consistency of the CRM when the dose-toxicity curve is not monotone and its application to the POCRM.
    Saha PT; Fine JP; Ivanova A
    Stat Med; 2021 Apr; 40(8):2073-2082. PubMed ID: 33588519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new function for drug combination dose finding trials.
    Xiao J; Zhang W
    Sci Rep; 2024 Feb; 14(1):3483. PubMed ID: 38346971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I design for completely or partially ordered treatment schedules.
    Wages NA; O'Quigley J; Conaway MR
    Stat Med; 2014 Feb; 33(4):569-79. PubMed ID: 24114957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRM2DIM: A SAS macro for implementing the dual-agent Bayesian continual reassessment method.
    Bayar MA; Ivanova A; Le Teuff G
    Comput Methods Programs Biomed; 2019 Jul; 176():211-223. PubMed ID: 31200907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Local continual reassessment methods for dose finding and optimization in drug-combination trials.
    Zhang J; Yan F; Wages NA; Lin R
    Stat Methods Med Res; 2023 Oct; 32(10):2049-2063. PubMed ID: 37593951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specifications of a continual reassessment method design for phase I trials of combined drugs.
    Wages NA; Conaway MR
    Pharm Stat; 2013; 12(4):217-24. PubMed ID: 23729323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Applications of the partial-order continual reassessment method in the early development of treatment combinations.
    Wages NA; Dillon PM; Portell CA; Slingluff CL; Petroni GR
    Clin Trials; 2024 Jun; 21(3):331-339. PubMed ID: 38554038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bayesian optimization design for finding a maximum tolerated dose combination in phase I clinical trials.
    Takahashi A; Suzuki T
    Int J Biostat; 2021 Apr; 18(1):39-56. PubMed ID: 33818029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential continual reassessment method for two-dimensional dose finding.
    Yuan Y; Yin G
    Stat Med; 2008 Nov; 27(27):5664-78. PubMed ID: 18618901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implementing the time-to-event continual reassessment method in the presence of partial orders in a phase I head and neck cancer trial.
    Patel A; Brock K; Slade D; Gaunt C; Kong A; Mehanna H; Billingham L; Gaunt P
    BMC Med Res Methodol; 2024 Jan; 24(1):11. PubMed ID: 38218799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A surface-free design for phase I dual-agent combination trials.
    Mozgunov P; Gasparini M; Jaki T
    Stat Methods Med Res; 2020 Oct; 29(10):3093-3109. PubMed ID: 32338145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I dose-escalation oncology trials with sequential multiple schedules.
    Günhan BK; Weber S; Seroutou A; Friede T
    BMC Med Res Methodol; 2021 Apr; 21(1):69. PubMed ID: 33853539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Shift models for dose-finding in partially ordered groups.
    Horton BJ; Wages NA; Conaway MR
    Clin Trials; 2019 Feb; 16(1):32-40. PubMed ID: 30309262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How to design a dose-finding study using the continual reassessment method.
    Wheeler GM; Mander AP; Bedding A; Brock K; Cornelius V; Grieve AP; Jaki T; Love SB; Odondi L; Weir CJ; Yap C; Bond SJ
    BMC Med Res Methodol; 2019 Jan; 19(1):18. PubMed ID: 30658575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extending the Continual Reassessment Method to accommodate step-up dosing in Phase I trials.
    Braun TM; Mercier F
    Stat Med; 2022 Sep; 41(20):3975-3990. PubMed ID: 35662077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Bayesian dose-finding design for outcomes evaluated with uncertainty.
    Schipper MJ; Yuan Y; Taylor JM; Ten Haken RK; Tsien C; Lawrence TS
    Clin Trials; 2021 Jun; 18(3):279-285. PubMed ID: 33884907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.